Shield Therapeutics Share Price (STX)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Shield Therapeutics	LSE:STX	London	Ordinary Share	GB00BYV81293	ORD 1.5P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+0.00p	+0.00%	35.00p	325,276	16:17:31

Bid Price		Offer Price	High Price	Low Price	Open Price
34.00p		36.00p	35.00p	34.50p	35.00p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.64	-20.99	-17.00		40.6

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), N4 Pharma (N4P), Port Erin (PEBI)

Shield Therapeutics (STX) Latest News

Shield Therapeutics News

Date	Time	Source	Headline
19/9/2018	12:09	ALNC	Shield Therapeutics Interim Loss Narrows, Ferracru Wins Contract
19/9/2018	07:17	ALNCF	Alliance News Flash Headline
19/9/2018	07:14	UKREG	Shield Therapeutics PLC Licence for the commercialisation of Feraccru
19/9/2018	07:12	UKREG	Shield Therapeutics PLC Interim Results
13/9/2018	11:51	ALNC	Shield Therapeutics Completes Recruitment For Feraccru Trial
13/9/2018	07:00	UKREG	Shield Therapeutics PLC AEGIS-H2H Completion of Recruitment
26/7/2018	13:05	ALNC	Shield Therapeutics Appoints Hans-Peter Hasler To Board
26/7/2018	07:02	UKREG	Shield Therapeutics PLC Appointment of Non-Executive Director
23/7/2018	13:27	ALNC	Shield Therapeutics Seeks Funding Partners Ahead Of US FDA Submission
23/7/2018	07:00	UKREG	Shield Therapeutics PLC Business Update

More Shield Therapeutics News

Shield Therapeutics Takeover Rumours

Shield Therapeutics (STX) Share Charts

1 Year Shield Therapeutics Chart

1 Month Shield Therapeutics Chart

Intraday Shield Therapeutics Chart

Shield Therapeutics (STX) Discussions and Chat

Shield Therapeutics Forums and Chat

Date	Time	Title	Posts
21/9/2018	07:34	Shield Therapeutics	43
28/2/2018	10:20	Seagate Technology	2,655

Add a New Thread

Shield Therapeutics (STX) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Shield Therapeutics trades in real-time

Shield Therapeutics (STX) Top Chat Posts

Date	Subject
23/9/2018 09:20	Shield Therapeutics Daily Update: Shield Therapeutics is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 35p. Shield Therapeutics has a 4 week average price of 30.50p and a 12 week average price of 30p. The 1 year high share price is 160p while the 1 year low share price is currently 13p. There are currently 116,102,621 shares in issue and the average daily traded volume is 481,357 shares. The market capitalisation of Shield Therapeutics is £40,635,917.35. Read Full Thread Reply
13/9/2018 07:07	ny boy: Tick tock, another step closer this morning! https://uk.advfn.com/stock-market/london/shield-therapeutics-STX/share-news/Shield-Therapeutics-PLC-AEGIS-H2H-Completion-of-Re/78248295 Read Full Thread Follow Reply
17/10/2012 12:47	babywolf: Hi Bracke Very pleased for you re BP! My current position: 6,000 STX short at 25.81. Was hopeful that Intel and IBM's disappointing figures last night might aid my shorts. I say "was" as the pre-market STX price doesnt appear to be affected. Read Full Thread Follow Reply
30/8/2012 14:56	babywolf: hi Bracke Latest on STX: $20.5M of STX sold by Stephen Luczo on 08/27/2012 August 29, 2012By: Jason Zucchettojason@marketbrief.com View: Form 4 Filing Luczo Stephen J sold 607,231 shares of Seagate Technology Plc stock, or $20,506,312 worth, as noted in an SEC Filing today. As reported in the filing, the transactions occurred on August 27, 2012. After the transaction, Luczo Stephen J's stake was reported as 648,805 shares of Seagate Technology Plc stock. In addition, Luczo Stephen J performed several other transactions, including using transaction codes 'M' (exercise, usually of options). As noted on August 29, 2012, Luczo Stephen J's sale was done directly over 1 transaction on August 27, 2012. The share price for the transaction was $33.77 according to the regulatory filing detailing the trade. If we look over the past 12 months, Luczo Stephen J has sold a total of 607,231 shares of Seagate Technology Plc, proceeds from the sale totaled $20,506,312. Over the same time period, Luczo Stephen J has purchased no shares of Seagate Technology Plc stock. Luczo Stephen J has also performed other transactions including gifts , and exercise of options . Let's take a quick, high-level look at insider trading at Seagate Technology Plc over the past 12 months. A total of 8,978,283 shares of Seagate Technology Plc stock was sold by insiders, totaling $226,136,048. Over the same time 12 month time period, no shares of Seagate Technology Plc were purchased by company insiders. Coming down as we speak. Not sure you know but I hold 9,000. I could deleverage right now - and nearly did that yesterday - but right now, glad I didnt. My average buy price: $29.23. WOuld you wait for the share price to come down lower or, I could sell those in profit and offset it against the losses. Looking at the different tranches to see what would best work. I could take 4500 off the table but it would leave me with 4500 at a ghastly average of $24.50. There has been a pattern of it opening and going lower very quickly and then recovering throughout the day but then to sink lower at the end. By pattern, I mean in the last week or so. About to plough through the data re BARC on analysts' opinion of new CEO and the possible SFO prosecution. Are you in any trades right now Bracke? Read Full Thread Follow Reply
01/8/2012 12:04	babywolf: An excerpt from an article on STX re comments made in the conference call following the results: "The most encouraging news could be found in the company's guidance on its share buyback and dividend policy. Seagate's CEO Steve Luczo stated the following: We are on plan to reduce our share count to 350 million ordinary shares outstanding by calendar year-end 2012. Assuming market and macroeconomic conditions and the company's performance and valuation metrics are similar to what they are today, we plan to reduce our share count to 250 million ordinary shares by calendar year-end 2014. Given the assumptions stated above, we expect that we will continue to increase our dividend payments in a meaningful manner while continuing our redemption plan over the course of the next several years. The current number of shares outstanding stands at 411 million as of June 2012 according to the company's recently released earnings. With expectations to reduce the share count to 350 million over the next 5 months, this immediate buyback would suggest that the company is willing to spend $1.83 billion at current market prices! Were the market capitalization of the company to stay at roughly $12.3 billion (as of July 31, 2012), the reduced share count would present a new share price of approximately $35 by the year's end. Factor in the increased dividend guidance, and it appears that Seagate may be in for a near-term bump up in value." Bracke - on the face of it, that means an average of 12m share repurchased per month to the end of this year - the same number ie 12m is the daily average. I wondered what your thoughts are on the share price - as you know, I would like to offload the shorts at minimum loss and wanted to check with you what the best way of doing this is: a) hedging with something else b) adding STX shorts on dips c) both a and b d) something I have not thought of! Read Full Thread Follow Reply
26/7/2012 12:59	babywolf: WatteNe - apologies! As a holder of BARC, did you see the article I am referring to? Just in case you did not: The Barclays Libor rate-fixing scandal could provide further shocks to the market by exposing severe flaws in the way the beleaguered bank is capitalised, Threadneedle UK Monthly Income manager Jonathan Barber has warned. The Citywire A-rated manager said he had not been tempted to buy into Barclays following recent share price weakness and believes the scandal surrounding the selling of interest rate swaps and Libor rate-rigging will only serve to expose weaknesses in the way it is capitalised, which could provide the market with a further shock. As a result, he expects another round of fundraising could be necessary for the bank. Speaking to Wealth Manager following his 10th anniversary on the fund, Barber said: 'Barclays is massively undercapitalised. 'If you think their balance sheet is roughly £1.5 trillion, which is the same size as UK GDP, and they have got a tangible common equity value trading at 40 pence in the £1 of about £50 billion to £60 billion in assets, so if you write off 2.5% of your assets you have got no equity left. 'And they are not the most conservative people in the world when it comes to marking to market versus marking to model. This is increasingly becoming evident. I think they need more equity than they can raise. That is one of the things which could go wrong... Barclays could be in a worse position than people think.' Read Full Thread Follow Reply
26/6/2012 15:33	babywolf: this is where my understanding of it all becomes underwhelming - I know now that for each seller there's a buyer and vice versa. I didnt know that until recently and thought an imbalance created a drop or rise - versus when a share price heads north or south, it just means cheaper=south and dearer=north... I think Read Full Thread Follow Reply
21/6/2012 15:37	babywolf: Just out: Morgan Stanley have revised EPS estimates on STX and Western Digital (the only other major hard disc drive manufacturer). No mention of downgrade on target share price but EPS being revised downwards (not massively though) isnt good. Just seen your post Bracke - thank you - 3,000 short at 21.72. Current loss -$4920. If the odds are strong that it will head down to $22 am tempted to add another 4000 to it now - another 4000 (my long is 7000). Would then make my average break even $22.65 Read Full Thread Follow Reply
20/6/2012 17:57	babywolf: Thanks Bracke - that is a great link. Now saved to my favourites. Re STX and my wanting to closing my 3000 short - I now know a little about the technical indicators but all bets are off when Bernanke speaks - I am assuming that it's best to use the indicators as exactly that - indicators - and that this all goes out the window on macro-data BUT it's temporary - would it be correct to say that the technicals reassert? Maybe mine is a stupid question because following the broadsides, the share price movements are then incorporated into the technical data... Read Full Thread Follow Reply
12/6/2012 17:23	babywolf: Hi again Bracke - sitting here watching the share price - it dipped quite a bit at the open which surprised me (silly me to be surprised at what a share price does!) but given the positive-spin posts on David Einhorn's increased stake, I WAS surprised. I sold 1000 of my 4000 short before the open and now sitting on 3000 that is building up a steady loss. Watching for the 23.60 mark which it may or may not make today. For the millionth time, bringing my brain back to the here and now - not what I coulda/shoulda/woulda done in not taking a huge position originally. I found a US website that has a STX message board with a varying degree of useful, intelligent data and debate - and a good dose of vitriol - not comfortable asking questions as the experienced traders on there don't have the patience with those like myself (thank you again for yours) Would like to implement your suggestion of hedging something else but a) my margin means that I could not risk getting the hedge going the wrong way and b) my ignorance and inexperience would have me not being confident in my choice. My current position means that my hedging the same share protects erosion of the margin - but as I posted earlier, a catch 22 just now. Hope you had a good day. Read Full Thread Follow Reply
07/6/2012 16:10	babywolf: Today's Overall Ratings: Up: 15 \| Down: 13 \| New: 26 Needham & Company maintains a 'Strong Buy' on Seagate Technology (NASDAQ: STX) price target lowered from $52 to $42. Analyst, Richard Kugele, said, "While a softer TAM for June (and potentially the balance of 2012) is frustrating, we believe that the stocks of both STX and WDC have more than accounted for this reduction in demand (with more than $5B in lost market cap just since May 16th vs. $700M in less sales). Once again trading meaningfully below 2x NTM EV/EBITDA, we would be buyers on this weakness and ahead of the likely upbeat analyst days in September." Needham lowers FY12 EPS estimate from $7.07 to $6.56 and FY13 from $10.63 to $8.91. So still a buy but target now $10 lower "with more than $5B in lost market cap just since May 16th vs. $700M in less sales". Hope that $5b doesnt go up much more. Read Full Thread Follow Reply

Shield Therapeutics share price data is direct from the London Stock Exchange

add chat code

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:40 V: D:20180924 03:58:43